Pipeline and Publications

Our goal: To employ our proprietary product engine to systematically identify and validate cellular drug targets that can modulate gene expression to treat the known root cause of genetically defined diseases.

pipeline 0919

Broad potential to change lives

Our approach to drug discovery and development is applicable across a large number of genetically defined diseases. We have developed a rigorous assessment and selection process to determine which of the approximately 7,000 rare, genetically defined diseases we intend to evaluate in drug target identification activities. We are applying our product engine to discover drug targets to modulate gene expression and develop product candidates for the potential treatment of the root cause of these diseases.

Muscle Disorders

muscles

CNS Disorders

central nervous system

Blood Disorders

red blood cells

We create value through our pipeline

By staying true to our passion and always prioritizing patients first, we plan to progress our programs and create significant value for all of our stakeholders.

 

Fulcrum Publications

April 15, 2024

Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial

Rabi Tawil MD, Prof Kathryn R Wagner MD, Johanna I Hamel MD, Doris G Leung MD, Jeffrey M Statland MD, Prof Leo H Wang MD, Angela Genge MD, Prof Sabrina Sacconi MD, Prof Hanns Lochmüller MD, David Reyes-Leiva MD, Prof Jordi Diaz-Manera MD, Jorge Alonso-Perez MD, Nuria Muelas PhD, Juan J Vilchez MD, Alan Pestronk MD, Summer Gibson MD, Prof Namita A Goyal MD, Prof Lawrence J Hayward MD, Nicholas Johnson MD, Samantha LoRusso MD, John G Jiang PhD

April 4, 2022

A phase 2, randomized, double-blind, placebo-controlled, 48-Week study of the efficacy and safety of losmapimodin subjects with FSHD: ReDUX4

Christopher Morabito, MD, CMO

April 4, 2022

An Open-Label Study of Losmapimod to Evaluate the Safety, Tolerability, and Biomarker and Clinical Outcome Assessment Changes in Subjects with FSHD1

Joost Kools, Nicol Voermans, Karlien Mul, Lucienne Ronco, John Jiang, Jennifer Shoskes, Kelly Marshall, Diego Cadavid, Michelle L. Mellion, Baziel van Engelen

April 4, 2022

Quantitative MuscleAnalysis in FSHD Using Whole-Body MRI: Composite Muscle Measurements for Cross-Sectional Analysis

Per Widholm, Markus Karlsson, André Ahlgren, Olof Dahlqvist-Leinhard, Rabi Tawil, Kathryn Wagner, Jeffrey Statland, Leo Wang, Perry Shieh, Baziel Van Engelen, Diego Cadavid, Lucienne Ronco, Adefowope Odueyungbo, Jay Han, Maya Hatch, Michelle L. Mellion

April 4, 2022

Reachable Workspace to Evaluate Efficacy of Losmapimodin Subjects with FSHD in Two Phase 2 Studies

Rabi Tawil, MD, Kathryn Wagner, MD, PhD, Jeffrey Statland, MD, Leo Wang, MD, PhD, Angela Genge, MD, Sabrina Sacconi, MD, PhD, Hanns Lochmüller, MD, PhD, David Reyes Leiva, MD, Jordi Diaz-Manera, MD, PhD, Nuria Muelas, MD, PhD, Juan J. Vilchez, MD, PhD, Alan Pestronk, MD, Summer Gibson, MD, Namita A. Goyal, MD, Johanna Hamel, MD, Jay Han, MD, Lawrence Hayward, MD, Nicholas Johnson, MD, Samantha LoRusso, MD, Miriam Freimer, MD, Perry B. Shieh, MD, PhD, Sankarasubramoney H. Subramony, MD, Doris Leung MD, PhD, Baziel van Engelen MD, PhD, Joost Kools, MD, John Jiang, PhD, L. Alejandro Rojas, PhD, Anthony Accorsi, PhD,Christopher Morabito, MD, Jennifer Shoskes, PharmD, Michelle L. Mellion, MD (first author)